Latest Cancer immunotherapy Stories
Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumors in preclinical experiments.
Created by Society for Immunotherapy of Cancer, this video was created to raise awareness about the excitement and the hope cancer immunotherapy clinical trials can offer patients with NSCLC today.
BLUE BELL, Pa., May 12, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
Tumors shrank or disappeared in some patients with advanced neuroblastoma in a Phase I study of an immune therapy manufactured at St.
-Proceeds to Support Advancement of Clinical Programs in Cancer Immunotherapy - SANTA MONICA, Calif., April 28, 2014 /PRNewswire/ -- Kite Pharma, Inc.
According to a new report from BCC Research the global market for cancer immunotherapies is expected to grow to nearly $67.9 billion by 2018, with a five-year compound annual growth rate (CAGR)
Leading Cancer Immunotherapy Startup also Bolsters Leadership Team with Two Key Appointments SEATTLE, April 24, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a biotechnology
Largest-ever gift to the Hutch promises to save lives by broadening the application of immunotherapy to lung, ovarian, pancreatic and colon cancers SEATTLE, April 7, 2014 /PRNewswire/
Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio,
Morgan Stanley's Head of Global Biotech Investment Banking Joins Leading Cancer Immunotherapy Startup SEATTLE, March 31, 2014 /PRNewswire/ -- Juno Therapeutics, a biotechnology company
- A woman chauffeur.
- A woman who operates an automobile.